ImmunityBio (IBRX) is back in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Anktiva plus BCG in BCG unresponsive papillary non muscle invasive bladder cancer.
See our latest analysis for ImmunityBio.
Despite the latest sBLA news and recent patents and supply deals around Anktiva and BCG, ImmunityBio’s share price has cooled, with a 7 day share price return down 9.41% and a 30 day share price return down 10.53%, although the year to date share price return of about 2.6x and 1 year total shareholder return of 185.38% still point to strong longer term momentum.
If you are looking beyond a single bladder cancer immunotherapy stock, this is a good moment to see what else is moving in healthcare focused AI, starting with 34 healthcare AI stocks.
With ImmunityBio now trading at US$7.22 against a US$15.25 analyst target and an intrinsic value implying about an 80% discount, you have to ask: is this a mispriced bladder cancer platform, or is the market already baking in future growth?
Most Popular Narrative: 46.5% Undervalued
ImmunityBio's most followed narrative pegs fair value at $13.50 per share, well above the last close at $7.22, so the gap to that story is wide.
The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.
Want to see what sits behind that gap between price and narrative fair value? The core of this story is sharp revenue growth, rising margins and a punchy future earnings multiple tied to 2029 expectations.
Result: Fair Value of $13.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this story could crack if ANKTIVA remains concentrated in bladder cancer, or if regulators slow or restrict approvals in new indications.
Find out about the key risks to this ImmunityBio narrative.
Next Steps
The story so far mixes excitement and real questions, so treat this as your cue to act quickly and stress test the full picture yourself with 2 key rewards and 4 important warning signs
Looking for more investment ideas?
If you stop with just one stock, you could miss opportunities that fit your style far better. Take a few minutes to scan other options with focused screeners.
- Spot potential turnaround stories at smaller price points by checking out 25 elite penny stocks with strong financials.
- Zero in on companies with solid finances and room for improvement by running the 49 high quality undervalued stocks.
- Prioritize resilience and support more stable outcomes by reviewing the 66 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com